Literature DB >> 20929279

Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.

Christopher A Koczor1, William Lewis.   

Abstract

IMPORTANCE OF THE FIELD: HIV/AIDS is a worldwide epidemic. While there remains no cure for the HIV-1 infection, nucleoside reverse transcriptase inhibitors (NRTIs) have helped transform the HIV-1 infection from a lethal disease into a chronic illness. Though NRTIs inhibit HIV-1 replication, they exhibit side effects in human tissues that appear to result from NRTI inhibition of human mitochondrial polymerase γ (pol γ). AREAS COVERED IN THIS REVIEW: this review discusses the current knowledge of NRTI-induced toxicity, specifically the inhibition of pol γ and the mitochondrial toxicity from incorporation of NRTIs into mitochondrial DNA. Details are discussed about general mechanisms of NRTI toxicity and how specific tissue toxicities in mitochondria relate to clinical manifestation. WHAT THE READER WILL GAIN: a detailed knowledge of the mitochondrial toxicity resulting from NRTI-inclusive therapies and related tissue toxicities are provided. This review presents both the molecular effects of NRTI usage on mitochondrial genetic homeostasis and energy metabolism as well as the clinical manifestations associated with NRTI toxicities. TAKE HOME MESSAGE: NRTIs remain a critical component of current HIV-1 treatment regimens. Future NRTIs should provide higher specificity for HIV-RT and lower incorporation by pol γ to minimize mitochondrial toxicity. Alternatively, therapeutic interventions to prevent or alleviate mitochondrial toxicity should be addressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20929279     DOI: 10.1517/17425255.2010.526602

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  39 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

Review 2.  HIV-associated sensory neuropathy: risk factors and genetics.

Authors:  Peter R Kamerman; Antonia L Wadley; Catherine L Cherry
Journal:  Curr Pain Headache Rep       Date:  2012-06

3.  Ethambutol induced toxic optic neuropathy in HIV positive patients.

Authors:  Hamzah Mustak; Graeme Rogers; Colin Cook
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

Review 4.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

5.  Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Authors:  D Rajotte; S Tremblay; A Pelletier; P Salois; L Bourgon; R Coulombe; S Mason; L Lamorte; C F Sturino; R Bethell
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

6.  Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy.

Authors:  Christopher M Bailey; Todd J Sullivan; Pinar Iyidogan; Julian Tirado-Rives; Raymond Chung; Juliana Ruiz-Caro; Ebrahim Mohamed; William L Jorgensen; William Jorgensen; Roger Hunter; Karen S Anderson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

7.  Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor.

Authors:  Wei Zhang; Michael A Parniak; Stefan G Sarafianos; Marilyn R Cost; Lisa C Rohan
Journal:  Int J Pharm       Date:  2013-12-09       Impact factor: 5.875

Review 8.  Aging and HIV/AIDS: pathogenetic role of therapeutic side effects.

Authors:  Rebecca A Torres; William Lewis
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

9.  Probing the structural and molecular basis of nucleotide selectivity by human mitochondrial DNA polymerase γ.

Authors:  Christal D Sohl; Michal R Szymanski; Andrea C Mislak; Christie K Shumate; Sheida Amiralaei; Raymond F Schinazi; Karen S Anderson; Y Whitney Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

10.  Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity.

Authors:  Christal D Sohl; Kamlendra Singh; Rajesh Kasiviswanathan; William C Copeland; Hiroaki Mitsuya; Stefan G Sarafianos; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.